Mirvetuximab Soravtansine

Phase 3

ImmunoGen, Inc. (IMGN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Epithelial Ovarian Cancer

View Full Landscape

Drug Information

Target Indication

Epithelial Ovarian Cancer

Clinical Trial

NCT04296890

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/14/2024

Elahere

Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

IMGN

ImmunoGen, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

Pegylated Liposomal DoxorubicinPhase 3

Epithelial Ovarian Cancer

Single high dose of liposomal amphotericin BPhase 3